16 May 2017
BPC-A-21-2017

Draft agenda
21st meeting of the Biocidal Products Committee (BPC)
27 – 29 June 2017
ECHA Conference Centre, Annankatu 18, Helsinki
Starts on 27 June at 09:30, ends on 29 June at 13:00

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-21-2017
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-20

BPC-M-20-2017
For agreement

5. – Administrative issues

5.1. Housekeeping issues

For information

5.2. Other administrative issues and report from other Committees

BPC-21-2017-01
For information

6. – Work programme for BPC

6.1. Revised BPC Work Programme 2017-2018

BPC-21-2017-02
For information

6.2. Outlook for BPC

BPC-21-2017-03
For information

7. – Applications for approval of active substances*

7.1. Draft BPC opinion on MBIT for PT 6

Previous discussion(s): WG-IV-2016

BPC-21-2017-05, A, B and C

For adoption

7.2. Draft BPC opinion on cholecalciferol for PT 14

Previous discussion(s): WG-I-2017

BPC-21-2017-06, A, B and C

For adoption

7.3. Draft BPC opinion on imiprothrin for PT 18

Previous discussion(s): WG-I-2017

BPC-21-2017-07, A, B and C

For adoption

7.4. Draft BPC opinion on MBO for PT 2, 6, 11, 12 and 13

Previous discussion(s): WG-II-2017

PT 2: BPC-21-2017-08A, B and C
PT 6: BPC-21-2017-09A, B and BPC-21-2017-08C
PT 11: BPC-21-2017-10A, B and BPC-21-2017-08C
PT 12: BPC-21-2017-11A, B and BPC-21-2017-08C
PT 13: BPC-21-2017-12A, B and BPC-21-2017-08C

For adoption

7.5. Draft BPC opinion on HPT for PT 2, 6, 11 and 13

Previous discussion(s): WG-II-2017

PT 2: BPC-21-2017-13A, B and C
PT 6: BPC-21-2017-14A, B and BPC-21-2017-13C
PT 11: BPC-21-2017-15A, B and BPC-21-2017-13C
PT 13: BPC-21-2017-16A, B and BPC-21-2017-13C

For adoption

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

7.6. Draft BPC opinion on copper for PT 2, 5 and 11

Previous discussion(s): WG-V-2016

PT 2: BPC-21-2017-17A, B and C
PT 5: BPC-21-2017-18A, B and BPC-21-2017-17C
PT 11: BPC-21-2017-19A, B and BPC-21-2017-17C

For adoption

7.7. Outcome of the written procedure on cypermethrin for PT 18

BPC-21-2017-20

For information

7.8. Revised Assessment Report following the submission of data after active substance approval for the renewal of difenacoum PT 14

BPC-21-2017-21

For agreement

Item 8 – Union authorisation

8.1. Update on Union authorisation

- **Timelines for the peer review process for applications for Union authorisation**
- **Revised BPC opinion template for Union authorisation**

BPC-21-2017-04, BPC-21-2017-22, BPC-21-2017-23

For information

Item 9 – Any other business

9.1. Outcome of the e-consultation on the open items identified at the ENV Working Groups

BPC-21-2017-24

For information

Item 10 – Agreement of the action points and conclusions

For agreement

Provisional timeline for the

21st meeting of the Biocidal Products Committee (BPC)

ECHA Conference Centre, Annankatu 18, Helsinki

27 June 2017: starts at 09:30; 29 June ends at 13:00

Please note that the timings indicated below are provisional and subject to possible change. They are distributed to participants on a preliminary basis.

Tuesday 27 June: morning session

Items 1-5	Opening items and administrative issues
Item 6	Work programme of the BPC 2017-18
Item 7.1	Draft BPC opinion on MBIT for PT 6

Tuesday 27 June: afternoon session

Item 7.2	Draft BPC opinion on cholecalciferol for PT 14
Item 7.3	Draft BPC opinion on imiprothrin for PT 18

Wednesday 28 June: morning session

Item 7.4	Draft BPC opinion on MBO for PT 2, 6, 11, 12 and 13

Wednesday 28 June: afternoon session

Item 7.5	Draft BPC opinion on HPT for PT 2, 6, 11 and 13

Thursday 29 June: morning session

Item 7.6	Draft BPC opinion on copper for PT 2, 5 and 11
Item 7.7	Outcome of the written procedure on cypermethrin for PT 18
Item 7.8	Revised Assessment Report following the submission of data after active substance approval for the renewal of difenacoum PT 14
Item 8	Update on Union authorisation
Item 9.1	Outcome of the e-consultation on theopen items identified at the ENV Working Groups
Item 10	Agreement of action points and conclusions

End of meeting

o0o